Showing results (141-150 of 431) with videos related to
Sort By:
Pageof 44
Respiration; International Review of Thoracic Diseases|December 21, 2022
Feasibility of Modified Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy: A Retrospective AnalysisAya Konno-Yamamoto, Yuji Matsumoto, Tatsuya Imabayashi, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 27, 2009
Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and dosesNaoko Sanuki-Fujimoto, Minako Sumi, Yoshinori Ito, et al.Lung Cancer (Amsterdam, Netherlands)|September 2, 2015
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutationsEri Sugiyama, Shigeki Umemura, Shogo Nomura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in JapanToshimi Takano, Tomoya Fukui, Yuichiro Ohe, et al.Journal of Cancer Research and Clinical Oncology|August 27, 2013
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinomaTatsuya Yoshida, Genichiro Ishii, Koichi Goto, et al.Thoracic Cancer|February 9, 2019
Mixed response to osimertinib and the beneficial effects of additional local therapyYuki Shinno, Yasushi Goto, Jun Sato, et al.Thoracic Cancer|February 15, 2019
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancerRyota Shibaki, Shuji Murakami, Yuki Shinno, et al.Thoracic Cancer|June 5, 2025
Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case ReportMariko Nishihara, Yuki Shinno, Yoshihiro Masui, et al.Japanese Journal of Clinical Oncology|August 21, 2018
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapyHironobu Hashimoto, Masakazu Abe, Takako Yanai, et al.JTO Clinical and Research Reports|September 30, 2021
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT StudyNobukazu Fujimoto, Morihito Okada, Takashi Kijima, et al.Pageof 44